Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paulo Véliz"'
Autor:
Angela Roco, Elena Nieto, Marcelo Suárez, Mario Rojo, Maria Paz Bertoglia, Gabriel Verón, Francisca Tamayo, Annabella Arredondo, Daniela Cruz, Jessica Muñoz, Gabriela Bravo, Patricio Salas, Fanny Mejías, Gerald Godoy, Paulo Véliz, Luis Abel Quiñones
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundVitamin K antagonists (VKA) are used as prophylaxis for thromboembolic events in patients with cardiovascular diseases. The most common VKA are warfarin and acenocoumarol. These drugs have a narrow therapeutic margin and high inter-individu
Externí odkaz:
https://doaj.org/article/1cf9186de83e4ef191387e96b937c8fa
Autor:
Mario Rojo MSc, Angela Margarita Roco PhD, Marcelo Suarez MSc, Maria Alejandra Lavanderos PhD, Gabriel Verón MSc, Maria Paz Bertoglia PhD, Annabella Arredondo MD, Elena Nieto MD, Juan Carlos Rubilar MSc, Francisca Tamayo PCh, Daniela Cruz MSc, Jessica Muñoz MSc, Gabriela Bravo MSc, Patricio Salas MD, Fanny Mejías MD, Paulo Véliz MSc, Gerald Godoy MSc, Nelson Miguel Varela PhD, G. Llull MSc, Luis Abel Quiñones PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Despite the development of new oral agents over the last decade, vitamin K antagonists (VKAs) remain the most widely used anticoagulants for treating and preventing thromboembolism worldwide. In Chile, the Ministry of Health indicates that acenocouma
Externí odkaz:
https://doaj.org/article/b3dbe867447c497f89dcb22acc4925d3
Autor:
Gerald Godoy, María A Lavanderos, Patricio Salas, Jessica Muñoz, G. Llull, Daniela Cruz, Francisca Tamayo, Gabriela Bravo, Luis A. Quiñones, Fanny Mejías, Nelson Varela, Mario Rojo, Annabella Arredondo, Gabriel Verón, María Paz Bertoglia, Ángela Roco, Juan Carlos Rubilar, Paulo Véliz, Elena Nieto, Suárez M
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Indexación: Scopus. Despite the development of new oral agents over the last decade, vitamin K antagonists (VKAs) remain the most widely used anticoagulants for treating and preventing thromboembolism worldwide. In Chile, the Ministry of Health indi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::801ea53e5bbd8ad2be4d3acf2f80b738
https://doaj.org/article/b3dbe867447c497f89dcb22acc4925d3
https://doaj.org/article/b3dbe867447c497f89dcb22acc4925d3